Insomnia

Insomnia is an inability to fall or remain asleep, or a complete absence of any drive toward sleep, arising acutely as a drug effect.

As such it is dose-proportional and eases as the substance wears off, distinguishing it from a chronic sleep condition. It ranges from mild difficulty winding down to a full suspension of the sleep urge across an entire active window.

Insomnia is among the more commonly reported adverse effects of activating compounds. It is most commonly induced at moderate to high doses under psychedelics such as LSD and psilocybin mushrooms and stimulants such as amphetamine; it also appears under nootropics such as meclofenoxate and phenylpiracetam, and under entactogens such as MDAI, where residual arousal can persist well past the subjective peak.

Insomnia is felt as a persistent wakefulness that resists effort: the body may be exhausted but the mind remains unnaturally alert, cycling through thoughts with no inclination toward rest.

Lying still can feel uncomfortable — restless tension in the limbs, a mildly elevated heart rate, and a heightened sensitivity to sound or light that makes the environment feel incompatible with sleep. Attempting to force sleep tends to deepen the frustration, and that frustration sustains wakefulness in turn.

At higher doses under psychedelics and stimulants, the alertness can feel entirely involuntary, as though the sleep-onset mechanism has been bypassed.

Insomnia arises through different pathways depending on the drug class:

• Stimulants — elevate dopamine and norepinephrine, suppressing adenosine-driven sleep pressure and sustaining cortical arousal well past the subjective peak.
• Psychedelics — act on 5-HT2A receptors, producing heightened sensory and cognitive activation that is physiologically incompatible with sleep onset.
• Nootropics — cholinergic and catecholaminergic compounds such as meclofenoxate and phenylpiracetam raise cortical activation and can delay sleep onset substantially when taken late in the day.
• Entactogens — produce serotonergic and monoaminergic stimulation that sustains wakefulness beyond the subjective peak.

How much each pathway contributes in a given case is not fully understood.

Who experiences it, and how strongly, varies widely. Higher doses and later timing of administration raise both the likelihood and duration of sleeplessness.

It is worsened by high ambient stimulation, pre-existing sleep debt, and anxious anticipation of the difficulty sleeping — especially under psychedelics and stimulants — and in people with a prior history of insomnia or generally light sleep.

Expectation feeds it: going in already worried about losing a night's sleep tends to be self-fulfilling. Adequate time between administration and an intended sleep window is the most reliable moderating factor.